Molecular Loop Biosciences v. Illumina: NGS Patent Suit Stayed for IPR
Molecular Loop Biosciences filed suit against Illumina and its subsidiary Verinata Health in the Delaware District Court, asserting three next-generation sequencing patents against the TruSight Oncology 500 platform. After 241 days, the court administratively closed the case pending inter partes review proceedings at the PTAB.
NGS infringement dispute paused as PTAB reviews asserted patents
Molecular Loop Biosciences, Inc. filed this infringement action on June 10, 2024 in the United States District Court for the District of Delaware, naming Illumina, Inc. and its subsidiary Verinata Health, Inc. as co-defendants. The complaint centered on three U.S. patents — US11768200B2, US11840730B1, and US11041852B2 — all directed to next-generation sequencing technology, asserted against Illumina’s TruSight Oncology 500 product.
The district court proceeding was stayed on February 6, 2025, in light of inter partes review proceedings pending before the Patent Trial and Appeal Board. The court issued an order administratively closing the case and dismissing a pending motion (D.I. 21) with leave to renew or refile if and when the stay is lifted. The parties are required to notify the court once the IPR proceedings are resolved so the case may be reopened.
The 241-day trajectory from filing to administrative closure suggests the IPR petitions were filed relatively promptly after the district court complaint — a pattern consistent with defendants seeking to challenge patent validity before expending resources on claim construction and discovery. The public record does not reveal the identity of the IPR petitioner(s), the specific grounds of challenge, or the PTAB’s institution decision, all of which will materially shape whether and how the district court litigation resumes.
Filing to Case Stayed in 241 days
241 days from filing to administrative closure — shorter than median patent case duration in D. Del.
Case stayed pending IPR: what the administrative closure means
Administrative closure is not a final judgment
An administrative closure in response to a stay is a docket-management tool, not a dismissal or merits ruling. The district court retains full jurisdiction. Once the PTAB resolves the pending IPR proceedings — whether by institution denial, final written decision, or settlement — the parties must notify the court, which may then reopen the case and schedule further proceedings. No claims have been adjudicated and no rights have been waived.
Stay — no merits dispositionMolecular Loop’s infringement claims are suspended, not abandoned
A stay preserves Molecular Loop’s ability to pursue infringement damages and injunctive relief if the asserted patents survive IPR. However, any PTAB decision cancelling or amending claims would significantly constrain the scope of the district court case on reopening. The outcome of IPR proceedings is therefore the critical variable determining whether and in what form this litigation continues.
Claims preserved pending PTABIllumina shifts the battleground to the PTAB
By securing a stay pending IPR, Illumina and Verinata Health have moved validity challenges to a forum historically more receptive to patent challengers. A successful IPR — even partial claim cancellation — would weaken or eliminate the patent basis for this suit before district court merits litigation begins. The dismissal of the pending motion with leave to renew signals the court anticipates potential reinstatement.
IPR as defensive strategyNGS oncology IP remains actively contested terrain
This case reflects the broader pattern of NGS platform developers facing patent assertions from upstream technology holders. The TruSight Oncology 500 is a high-value clinical diagnostics product; successful enforcement would carry meaningful commercial consequences. Companies across the oncology sequencing supply chain should monitor PTAB dockets covering sequencing method and composition patents for early signals of claim stability.
NGS oncology IP riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Molecular Loop Biosciences, Inc. | Company | Genomics biotechnology company — holder of US11768200B2, US11840730B1, and US11041852B2Search in Eureka ↗ |
| Defendant | Illumina, Inc. | Company | Illumina, Inc. — global leader in next-generation sequencing instruments and consumables; Verinata Health, Inc. subsidiarySearch in Eureka ↗ |
| Co-Defendant | Verinata Health, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Ashley DaBiere | Attorney | Counsel for Molecular Loop Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Brian D. Matty | Attorney | Counsel for Molecular Loop Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Brian E. Farnan | Attorney | Counsel for Molecular Loop Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Deborah J. Mariottini | Attorney | Counsel for Molecular Loop Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kevin Goon | Attorney | Counsel for Molecular Loop Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael J. Farnan | Attorney | Counsel for Molecular Loop Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Farnan LLP | Law Firm | Representing Molecular Loop Biosciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Bradford J. Badke | Attorney | Counsel for Illumina, Inc.Search in Eureka ↗ |
| Defendant counsel | Ching-Lee Fukuda | Attorney | Counsel for Illumina, Inc.Search in Eureka ↗ |
| Defendant counsel | Joshua J. Fougere | Attorney | Counsel for Illumina, Inc.Search in Eureka ↗ |
| Defendant counsel | Kelly E. Farnan | Attorney | Counsel for Illumina, Inc.Search in Eureka ↗ |
| Defendant counsel | Leif E. Peterson , II | Attorney | Counsel for Illumina, Inc.Search in Eureka ↗ |
| Defendant counsel | Thomas A. Broughan , III | Attorney | Counsel for Illumina, Inc.Search in Eureka ↗ |
| Defendant law firm | Richards Layton & Finger PA | Law Firm | Representing Illumina, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order reflects a standard administrative stay in response to parallel PTAB proceedings — a discretionary docket-management mechanism that the District of Delaware grants where IPR proceedings present a reasonable likelihood of narrowing or eliminating asserted claims. The dismissal of D.I. 21 with leave to renew is procedurally significant: it avoids adjudicating a potentially moot motion while preserving Molecular Loop’s ability to re-assert it should the case reopen. No merits findings have been made on infringement, validity, or damages.
US11768200B2, US11840730B1 & US11041852B2 — NGS sequencing methods and compositions
The three asserted patents — US11768200B2 (application US17/339527), US11840730B1 (application US16/952764), and US11041852B2 (application US17/149504) — are directed to next-generation sequencing technology. Their application numbers span filings from 2020–2021, placing them in a period of rapid innovation in clinical NGS panel design. The patents appear to cover methods and/or compositions relevant to sequencing-based oncology diagnostics, a technically dense domain involving library preparation, target enrichment, and bioinformatic processing.
The assertion of all three patents against a single product — TruSight Oncology 500 — suggests Molecular Loop views them as a coordinated portfolio covering complementary aspects of the sequencing workflow. For competitors offering clinical oncology sequencing panels, the survival or cancellation of these patents at the PTAB will be a material event. Companies developing or commercializing NGS-based tumor profiling panels should monitor PTAB proceedings closely and conduct FTO reviews against each patent’s claims independently.
Should you run an FTO against US11768200B2, US11840730B1, and US11041852B2?
Any company developing, manufacturing, or commercializing next-generation sequencing panels for oncology — particularly comprehensive genomic profiling or tumor mutational burden assays — should treat these three patents as active FTO risks until PTAB proceedings conclude. The asserted patents cover sequencing methods and compositions that may read on widely used library preparation and enrichment workflows, not merely on Illumina’s specific product design.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US11768200B2, US11840730B1, and US11041852B2 against your product’s technical workflow, flag prior art relevant to PTAB proceedings, and surface related continuations or divisionals in Molecular Loop’s portfolio that could generate follow-on assertions. Set up patent family monitoring to receive alerts when PTAB decisions are issued on these applications.
Run a freedom-to-operate analysis on US11768200B2 to assess your product’s exposure
Run FTO in Eureka →Similar NGS and oncology diagnostics patent cases in D. Delaware
Cases involving next-generation sequencing and oncology diagnostics patents litigated in the District of Delaware, with parallel PTAB proceedings or comparable IPR stay patterns.
What this case signals for the NGS and oncology diagnostics IP landscape
A PTAB stay in a high-profile NGS infringement action concentrates risk at the validity layer — with district court exposure held in reserve.
IPR timing can reset litigation economics for both sides
Illumina’s apparent success in obtaining a stay pending IPR is consistent with a strategy of front-loading validity challenges before claim construction and discovery costs accumulate. For patent holders like Molecular Loop, this means the PTAB outcome — not the district court schedule — now controls litigation timeline and leverage. Early FTO analysis against all three asserted patents is material to any commercial planning.
Three-patent assertion raises claim-cancellation risk at PTAB
When a plaintiff asserts multiple related patents, defendants can file multiple IPR petitions and seek estoppel-limiting outcomes across the portfolio. If the PTAB cancels claims in even one of the three asserted patents, it narrows the reopened district court case. Monitoring IPR dockets for US11768200B2, US11840730B1, and US11041852B2 is essential for any competitor or licensee in the NGS space.
Molecular v Illumina — key questions answered
As of February 6, 2025, the case is administratively closed. The District of Delaware stayed proceedings pending inter partes review of the three asserted patents before the PTAB. The parties must notify the court once IPR proceedings conclude so the case may be reopened.
Molecular Loop asserted three patents: US11768200B2, US11840730B1, and US11041852B2. All three relate to next-generation sequencing technology and were filed between 2020 and 2021. They were asserted against Illumina’s TruSight Oncology 500 clinical NGS panel product.
An administrative closure is not a dismissal or final judgment. The court retains jurisdiction and the infringement claims remain live. If the asserted patents survive PTAB review with enforceable claims, the case can be reopened and litigation will resume. PTAB cancellation of claims would narrow or potentially moot portions of the infringement case.
Verinata Health is an Illumina subsidiary. Naming it as a co-defendant suggests Molecular Loop is targeting both corporate entities for acts of alleged infringement, potentially related to development or commercialization of the accused product. This is consistent with multi-defendant strategies aimed at maximizing damages exposure and foreclosing corporate structure defenses.
If Illumina (or a related entity) filed the IPR petitions, any grounds raised and decided at the PTAB trigger estoppel under 35 U.S.C. § 315(e)(2), barring those grounds in the district court. This means Illumina must choose IPR grounds carefully — a final written decision adverse to Illumina on validity forecloses re-litigation of those same grounds before the district court judge.
PatSnap Eureka searches patents and litigation data to answer instantly.